Safety of high-dose Amphotericin B lipid complex
Infection with Aspergillus species carries a high mortality in patients with liver disease, 1, 2 and amphotericin B remains the agent of choice for the treatment of aspergillus infections. Lipid-based formulations of amphotericin B are less toxic than the conventional form of the drug. 3 Amphotericin B lipid complex (Abelcet) is a lipid formulation with a high amphotericin B/lipid ratio (1:1). 4 Pharmacokinetic studies indicate that this formulation achieves lower peak plasma concentrations, but higher tissue levels than the other lipid formulations of amphotericin B (liposomal amphotericin B (AmBisome) and amphotericin B colloidal dispersion). 5 Clinical analyses suggest that Abelcet is a safe and effective agent for the treatment of invasive fungal infection (IFI). [6] [7] [8] [9] Ringdén et al 10 report a high rate of toxicity associated with the use of high-dose Abelcet in a mixed group of critically ill patients. In their retrospective review, 19 patients received Abelcet at a mean dose of 4.1 mg/kg once daily, and 14 (74%) suffered side-effects requiring discontinuation of the drug. They acknowledge that side-effects of Abelcet were rarely seen in other analyses, 8, 9 and they encourage others to report their experiences with this drug.
In the Birmingham Liver Unit, during an 18 month period commencing November 1996, we treated 30 patients (10 male, 20 female; median age 49.5 years, range 20-68 years) with Abelcet at 5 mg/kg once daily (32 treatment episodes).
Eighteen patients underwent 20 liver transplants (LT) (underlying diagnoses: primary biliary cirrhosis, seven; fulminant hepatic failure, three; retransplantation, three; hepatitis C virus cirrhosis, three; primary sclerosing cholangitis, two; hepatitis B virus cirrhosis/hepatoma, one; cryptogenic cirrhosis, one), and received Abelcet (20 treatment episodes) following LT. Of these, 11 treatment episodes were part of a prospective audit to assess drug safety and efficacy as prophylaxis post-LT (unpublished data). The reasons for the other nine treatment episodes were: IFI in two, suspected IFI in two, and at risk for IFI (empirical) Abelcet for the following reasons: IFI in three, suspected IFI in four, and empirical in five. Overall, the median duration of treatment was 8 days (range, 1-73 days), and median total Abelcet dosage per patient was 2.4 g (range, 0.3-25.6 g per patient). Note that the comparative figures in the review by Ringdén et al 10 were 3 days (range, 1-19 days) and 0.9 g (range, 0.3-6.5 g). All patients in our analysis received a test dose of Abelcet (1 mg) before receiving the first complete dose. No patient received premedication with antihistamine. All LT patients received immunosuppression with corticosteroid, azathioprine and either cyclosporine or tacrolimus.
Fifteen of 30 patients died, but no deaths were attributed to Abelcet. No adverse reactions were observed in 24 of 30 patients receiving Abelcet. The drug was discontinued in three of 30 patients because of fever and chills, but it was restarted 2 days later in one of these patients, who went on to receive a further eight doses without complication. Thus, Abelcet was permanently discontinued in only two of 30 patients (6.7%), and in both patients symptoms resolved following administration of antihistamine and corticosteroid. Note that this compares with a 74% discontinuation rate reported by Ringdén et al. 10 Of these two patients, one was converted to fluconazole, but died of cryptococcal meningitis 8 days later. The other patient was converted initially to fluconazole, then to AmBisome and finally to conventional amphotericin B, but died of probable Candida peritonitis 1 month later. Three other patients experienced fever and chills; of these, symptoms improved in one patient following treatment with antihistamine and corticosteroid. Symptoms in the other two patients did not require treatment and improved with subsequent doses of Abelcet. These two patients received a further two and eight doses of Abelcet, respectively. Diminution of symptoms with successive doses of Abelcet has previously been documented. 9 We did not observe any renal toxicity which was temporally related to Abelcet administration. For all 32 treatment episodes, mean serum creatinine level was 197 Ϯ 21 mol/l (mean Ϯ s.e.) before and 191 Ϯ 15 mol/l at the end of Abelcet, P = 0.74 (NS), t-test for paired samples. For cases receiving cyclosporine or tacrolimus (n = 20), the corresponding values were 187 Ϯ 25 mol/l before and 187 Ϯ 16 mol/l at the end of Abelcet, P = 0.99 (NS); for the remaining 12 cases the values were 215 Ϯ 37 mol/l before and 196 Ϯ 31 mol/l at the end of Abelcet, P = 0.617 (NS). The maximum serum creatinine level observed during Abelcet treatment was 449 mol/l, but in this patient the serum creatinine level before Abelcet was already markedly elevated (434 mol/l).
Of 32 treatment episodes, renal support (in the form of continuous veno-venous haemofiltration, CVVH), was commenced in six cases during Abelcet treatment. In four of six cases, patients were receiving concomitant nephrotoxic medication; despite this, renal recovery was observed in two of these four cases during ongoing Abelcet, allowing cessation of CVVH. Seventeen of 32 episodes did not require renal support at any stage; mean serum creatinine level for these cases was not affected by Abelcet (181 Ϯ 30 mol/l before and 187 Ϯ 25 mol/l at the end of Abelcet, P = 0.82 (NS)). Nine of 30 cases were already receiving renal support before commencing Abelcet, reflecting the critically ill nature of the patient population.
Our experience with Abelcet is that discontinuation due to adverse events was rarely seen (6.7%); this is very similar to the discontinuation rate reported in several other studies (0-11%), [6] [7] [8] [9] but differs strikingly from that observed by Ringdén et al (74%). 10 The patients we report received Abelcet at a similar dose to those patients reviewed by Ringdén et al 10 although the patients in our series received the drug for a longer period and at a higher total dose per patient. The majority of patients reported by Ringdén et al 10 suffered from haematological malignancies (18 of 19), and most had either undergone bone marrow transplantation or were receiving chemotherapy, whilst only one patient underwent LT. In contrast, 20 of 30 patients in our group underwent LT, and the remaining 10 patients suffered from hepatic, hepatobiliary or pancreatic disease. It is unlikely that the differences observed in Abelcet discontinuation rate can be explained by the differences in patient populations, as other studies reporting a low incidence of serious side-effects also focused on patients with haematological malignancies. 6, 8, 9 Other reasons for discontinuation of Abelcet in the patients reported by Ringdén et al 10 were erythema, abnormality of liver function tests, severe vomiting, hypoxaemia, haemolysis and back pain. We did not observe any of these side-effects in temporal association with Abelcet infusion. At the time of commencement of Abelcet therapy in our analysis, many patients already had impaired liver function (as a feature of their underlying disease), and many were being mechanically ventilated for hypoxaemia secondary to critical respiratory disease. We did not observe any deterioration in these parameters which correlated with Abelcet administration.
It is difficult to reach a valid conclusion on the comparative safety of the different formulations of amphotericin B, on the basis of uncontrolled data obtained from diverse patient populations. Furthermore, these agents are usually administered at a time when patients with complex medical problems, already receiving multiple concomitant toxic drugs, are suffering a deterioration in their disease process; this makes safety analysis even more difficult, as acknowledged by others. 7 We agree with Ringdén et al 10 that randomised, comparative studies would be required to definitively demonstrate a difference in safety, tolerability and efficacy between these agents. In the absence of such studies, we suggest that units should audit their own experience, in a prospective manner where possible, and devise protocols accordingly. We have previously reported our experience with AmBisome. 11 In that review, 25 patients with presumed or suspected IFI post-LT received AmBisome (albeit at a lower dose, 3 mg/kg once daily) for a median of 11 days (range, 5-46 days). We did not observe any renal toxicity attributable to AmBisome, and no patient discontinued the drug because of an adverse event.
In our current analysis, Abelcet (at a higher dose, 5 mg/kg once daily) was not associated with renal or other toxicity, and treatment was permanently discontinued in only 6.7% of patients because of an adverse event.
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